Ciba turns down Biosignal compounds

By Dylan Bushell-Embling
Wednesday, 06 August, 2008

Global specialty chemical company Ciba Corporation has decided to stop testing Biosignal's [ASX: BOS] anti-microbial industrial compounds, citing major issues incorporating the product into theirs.

Ciba was evaluating whether it could incorporate the compounds into its PVC plastic and coatings, but found that doing so resulted in high temperatures during the processing stage and incompatibility with other components.

Representatives for Biosignal said the decision did not alter expectations for the viability of the compounds, stating that it still had evaluation agreements in place with a number of companies.

These include oil producer ConocoPhillips, sanitation product manufacturers Saraya Co, and leading agrichemicals and animal health companies.

Related News

Anti-inflammatory drug may help treat alcohol use disorder

A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...

Osteoarthritis study uncovers new genetic links, drug targets

The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...

How brain cells are affected by Tourette syndrome

US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd